Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer
复制标题
DOI：
10.1111/imj.12453
复制
发表时间：
2014-07-01
影响因子：
2.1
通讯作者：
Khattak, M. A.
中科院分区：
文献类型：
--
作者：
Martin, H. L.;Ohara, K.;Khattak, M. A.
背景：各种系统性炎症标志物在不同癌症中的预后意义已被探讨。这些标记可用于协助肿瘤诊所的决策。目的：本研究旨在探讨中性粒细胞-淋巴细胞比率（NLR）、血小板淋巴细胞比率（PLR）和改良格拉斯哥预后评分（mGPS）这三个系统性炎症因子对晚期胰腺癌患者预后的意义。方法：回顾性收集2008年1月1日至2012年12月31日在皇家珀斯医院接受治疗的晚期胰腺癌患者的资料。将比率分为NLR < 5 vs >= 5, PLR < 200 vs >= 200。改良格拉斯哥预后评分评分为：mGPS '0' = c反应蛋白（CRP）和白蛋白均正常，mGPS '1' = CRP升高< 10 mg/L, mGPS '2' = CRP升高> 10 mg/L和白蛋白< 35 g/L。进行了单因素和多因素分析。结果：124例患者的数据可评估。基于三个基于炎症的预后指标评估的中位生存期分别为：NLR < 5 vs >= 5 = 8.5个月vs 2.6个月（P = 0.0007；风险比（HR） 1.81）， PLR < 200 vs = 200 = 9.1个月vs . 4个月（P = 0.007; HR 1.64）， mGPS评分1,2,3分别= 8.3个月，9.6个月和1.8个月（P = 0.0004）。除了东部肿瘤合作组的预后状态外，NLR、PLR和mGPS在单因素和多因素分析中都是显著的独立预后指标。结论：我们的研究结果表明，来自常规血液检查的NLR、PLR和mGPS可作为临床有意义的生物标志物，将晚期胰腺癌患者分为不同的预后组。
Background: The prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to assist with decision-making in oncology clinics.Aim: The aim of this study was to investigate the prognostic significance of three systemic inflammation-based factors: neutrophil-lymphocyte ratio (NLR), plateletlymphocyte ratio (PLR) and modified Glasgow Prognostic Score (mGPS) in patients with advanced pancreatic cancer.Methods: Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as < 5 versus >= 5 for NLR and < 200 versus >= 200 for PLR. Modified Glasgow Prognostic Scores were scored as: mGPS '0' = both C-reactive protein (CRP) and albumin normal, mGPS '1' = elevated CRP < 10 mg/L and mGPS '2' = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out.Results: Data were evaluable for 124 patients. Median survivals based on the three inflammation-based prognostic markers evaluated were: NLR < 5 versus >= 5 = 8.5 months versus 2.6 months respectively (P = 0.0007; hazard ratio (HR) 1.81), PLR < 200 versus = 200 = 9.1 months versus 4 months respectively (P = 0.007; HR 1.64) and mGPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively (P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and mGPS were significant independent prognostic markers both on univariate as well as multivariate analysis.Conclusions: Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.